# A Phase II Study of Nivolumab + Ipilimumab in Advanced HCC Patients Who Have Progressed on First Line Atezolizumab + Bevacizumab

> **NCT05199285** · PHASE2 · TERMINATED · sponsor: **Academic and Community Cancer Research United** · enrollment: 15 (actual)

## Conditions studied

- BCLC Stage B Hepatocellular Carcinoma
- BCLC Stage C Hepatocellular Carcinoma
- Locally Advanced Hepatocellular Carcinoma
- Metastatic Hepatocellular Carcinoma
- Stage III Hepatocellular Carcinoma AJCC v8
- Stage IIIA Hepatocellular Carcinoma AJCC v8
- Stage IIIB Hepatocellular Carcinoma AJCC v8
- Stage IV Hepatocellular Carcinoma AJCC v8
- Stage IVA Hepatocellular Carcinoma AJCC v8
- Stage IVB Hepatocellular Carcinoma AJCC v8
- Unresectable Hepatocellular Carcinoma

## Interventions

- **BIOLOGICAL:** Ipilimumab
- **BIOLOGICAL:** Nivolumab

## Key facts

- **NCT ID:** NCT05199285
- **Lead sponsor:** Academic and Community Cancer Research United
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-01-19
- **Primary completion:** 2025-09-04
- **Final completion:** 2025-09-04
- **Target enrollment:** 15 (ACTUAL)
- **Why stopped:** Sponsor has withdrawn support for the study.
- **Last updated:** 2025-10-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05199285

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05199285, "A Phase II Study of Nivolumab + Ipilimumab in Advanced HCC Patients Who Have Progressed on First Line Atezolizumab + Bevacizumab". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05199285. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*